Browsing by Author Findlay, Michael

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)Citation
2008Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinomaDhillon, Haryana; Gebski, Val; Hargreaves, Carol; Nowak, Anna; Stockler, Martin; Cebon, Jonathon; Findlay, Michael; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAssessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma, Asia-Pacific Journal of Clinical Oncology, vol.4, N/A, 2008,pp 55-67
2017First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsGebski, Val; et al, Various; Findlay, Michael; Gibbs, Peter; Heinemann, Volker; Peeters, Marc; Ricke, Jens; Sharma, Navesh K; Taieb, Julien; Wasan, Harpreet; Weaver, Andrew; NH&MRC Clinical Trials CentreFirst-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials, The Lancet Oncology, vol.18, 9, 2017,pp 1159-1171
2002Histological tumour response to pre-operative combined modality therapy in locally advanced rectal cancerKoorey, David; Morgan, M; Solomon, Michael; Findlay, Michael; Painter, Dorothy; Stevens, G.; Tran, K.; Central Clinical School: Medicine; Surgery; Central Clinical School: SurgeryHistological tumour response to pre-operative combined modality therapy in locally advanced rectal cancer, Colorectal Disease, vol.4,(3),2002,pp 177-183
2003p53 and DCC immunohistochemistry in curative rectal cancer surgeryChapuis, Pierre; Koorey, David; Morgan, Michael; Solomon, Michael; Findlay, Michael; Newland, R.; Painter, Dorothy; Concord Clinical School: Surgery; Central Clinical School: Medicine; Northern Clinical School: Surgery; Central Clinical School: Surgeryp53 and DCC immunohistochemistry in curative rectal cancer surgery, International Journal of Colorectal Disease, vol.18,(3),2003,pp 188-195
2003P53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapyChapuis, Pierre; Clarke, Stephen; Koorey, David; Morgan, Michael; Saw, Robyn; Solomon, Michael; Findlay, Michael; Painter, Dorothy M.; Stevens, Graham; Concord Clinical School: Surgery; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Northern Clinical School: Surgery; Central Clinical School: Surgery; Central Clinical School: SurgeryP53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy, Diseases of the Colon and Rectum, vol.46,(2),2003,pp 192-202
2007A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group study 9601Boyer, Michael; Dhillon, Haryana; Gebski, Val; Yuen, Jennifer; Archer, Stephen; Cullingford, Graham L.; Davidson, Andrew; et, al; Findlay, Michael; Hargreaves, C; Johnston, Peter; Storey, David; Trotter, James; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreA pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group study 9601, ANZ Journal of Surgery, vol.77,(4),2007,pp 247-252
2016SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal CancerGebski, Val; et al, Various; Ferguson, Tom; Findlay, Michael; Hazel, Guy; Heinemann, Volker; Peeters, Marc; Perez, D; Ricke, Jens; Robinson, Bridget; Sharma, Navesh; Strickland, A. H.; NH&MRC Clinical Trials CentreSIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.34, 15, 2016,pp 1723-1731
2004Systemic Therapy For Advanced Hepatocellular Carcinoma: A Review.Nowak, Anna; Chow, Pierce K H; Findlay, Michael; School of Public Health: NH&MRC Clinical Trials CentreSystemic Therapy For Advanced Hepatocellular Carcinoma: A Review., European Journal Of Cancer, vol.40,(10),2004,pp 1474-1484
2005Use of Tamoxifen in Advanced-Stage Hepatocellular CarcinomaNowak, Anna; Stockler, Martin; Chow, Pierce K H; Findlay, Michael; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreUse of Tamoxifen in Advanced-Stage Hepatocellular Carcinoma, Cancer 2005, vol.103,(7),2005,pp 1408-1414